FDA Issues Guidance on Allowable Excess Volume for Injectables
The agency clarifies its requirements for allowable excess volume and labeled vial fill size in injectables and biologics.
FDA has issued guidance clarifying the Center for Drug Evaluation and Research’s and the Center of Biologics Evaluation and Research’s recommendations for allowable excess volume and labeled vial fill size in injectable drugs and biologics. The guidance describes when justification is required for proposed excess volume, the importance of appropriate fill volumes, and appropriate labeled vial fill sizes and dosing.
The guidance focuses on withdrawable volume and labeled vial fill size for injectables packaged in vials and ampules but does not address prefilled syringes, intravenous infusion bags, or noninjectables. FDA states that the recommendations apply to new drug applications, abbreviated new drug applications, biologics license applications, and supplements or other changes to these applications for new packaging or changes that affect fill volume.
Source: FDA
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
